Navigation Links
VirtualScopics Receives Issuance in Japan of Prominent Patent
Date:12/3/2009

ROCHESTER, N.Y., Dec. 3 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that its patent titled "System and Method for 4D Reconstruction and Visualization" recently received issuance in Japan.

VirtualScopics' Vice President of Technology and Product Development, Dr. Jonathan Riek, stated, "We are pleased that Japan has recognized the uniqueness of VirtualScopics' science by joining the United States, Germany, France, United Kingdom, and Israel in issuing this important patent." He further added, "It is this patent which served as the basis for the formation of the company in 2000 and continues to set us apart among imaging providers today. We've been able to build upon this patent to specifically develop our musculoskeletal image analysis tools." He concluded, "To date we've used these tools alone in over 90 musculoskeletal projects, assisting more than 15 leading pharmaceutical and medical device companies in the development of their drugs, devices and biologics."

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.


CONTACT:         Company Contact:
                 Molly Henderson
                 Chief Business and Financial Officer
                 500 Linden Oaks
                 Rochester, New York 14625
                 (585)249.6231

SOURCE VirtualScopics, Inc.


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 6, 2017  Medical professionals are expected ... while treating their patients. Medical simulations offer ... involving patients. Simulation provides a safe method ... out procedures, refine techniques and build confidence, ... new technology, such as augmented reality, will ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... of the much-anticipated fall event , Look Awesome This Autumn with CoolSculpting®. ... consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is Houston’s ...
(Date:9/20/2017)... ... 20, 2017 , ... Each year Athletic Trainers from around ... Association Annual Clinical Symposium and Expo. New research is revealed, evidence based practice ... are acknowledged by their peers with accolades and highly prestigious awards. This past ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Americans at risk of price gouging for their prescription drugs, according to a ... “Because Medicare isn’t negotiating on our behalf, there’s no consistency in drug pricing ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second ... of God; Second Edition” is the creation of published author, Brooks Rathell. , “We ... to talk to you about the financial favor of God. Not only does it ...
Breaking Medicine News(10 mins):